Events & Presentations
Board of Directors
Historic Stock Lookup
Galectin Therapeutics Announces Results From 12-Week Extension of Phase 2a Psoriasis Clinical Trial
August 25, 2016 | Press Release
Galectin Therapeutics Reports Second Quarter 2016 Financial Results and Provides Business Update
August 9, 2016 | Press Release
Galectin Therapeutics Announces Completion of Patient Recruitment in its Phase 2 Trial with GR-MD-02 in NASH Patients with Cirrhosis
August 2, 2016 | Press Release
What are galectins and why are they a good target for the treatment of NASH?
Are you conducting clinical trials with GR-MD-02? What results have you seen so far?
Why did you choose to become the CEO of Galectin Therapeutics?
Why is fatty liver disease called "the hidden epidemic?"
What is fibrosis and what role does it play in chronic diseases such as NASH?
Galectin Therapeutics, Inc.
Financial Tear Sheet
Filings & Reports
Stock price updates every 30 minutes.
2015 Year In Review
Latest Corporate Presentation
Media Fact Sheet
Corporate Fact Sheet
Sign up for our latest updates
© 2016 Galectin Therapeutics Inc. - All Rights Reserved
Disclaimer: This site may contain